Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > REGULATORY
REGULATORY
- MHLW Designates Everolimus, 3 Other Products as Orphan Drugs
December 16, 2011
- Public-Private Dialogue to Set Next Strategic Plan for Innovative Drug Discovery
December 15, 2011
- CSIMC Approves Draft Measures to Promote Generic Drug Use
December 15, 2011
- MHLW Notifies of Changes to Precautions for Warfarin Potassium Preparations
December 15, 2011
- ELD Issues Fully Revised GL for Clinical Evaluation of Sleep Medications
December 14, 2011
- Dr Nakamura’s Premature Retirement to Affect “Drug Discovery Support Organization” Project
December 14, 2011
- Government Decides FY2012 Tax Revision Outline, to Extend R&D Tax Break System by 2 Years
December 13, 2011
- Ruling Coalition Prioritizes Economic Evaluation, Other Programs for 2012 Special Budget Quota
December 12, 2011
- MHLW Issues Notification to Change Japanese Pronunciation of “Rivaroxaban” to “Rivah-roxaban”
December 12, 2011
- MOF Asks MHLW for Add’l 10% Price Cut for Long-listed Drugs
December 12, 2011
- Price Cuts for Long-listed Drugs Will Not Promote Generic Drug Use: Korosho in Negotiations with MOF
December 10, 2011
- 11 APIs/26 Products to Return Premium for New Drug Development
December 9, 2011
- MHLW Minister Komiyama Calls on Opposition to Join Efforts to Consider Third-Party Organization
December 9, 2011
- US FDA Begins Review of Risks of Serious Bleeding in Patients Taking Dabigatran
December 9, 2011
- NHI Drug Pricing Subcommittee to Apply 80% Rule for Combination Drugs to Injectables, Topical Drugs
December 8, 2011
- Gov’t Tax Commission Decides to Extend Temporary R&D Tax Credits
December 8, 2011
- CSIMC Submits Opinion on Medical Fee Revision Including Views of Both Healthcare Providers and Medical Bill Payers
December 8, 2011
- MHLW Proposes Penalty for Companies that Receive Premium but Refuse Development Requests
December 8, 2011
- Payers, Care Providers Agree at CSIMC on Need for Price Cuts for Long-listed Drugs
December 8, 2011
- Representatives of Payers, Care Providers Argue Against Freeze on Prices of Essential Drugs
December 8, 2011
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…